Skip to content

the Application of Transjugular Intrahepatic Portosystemic Shunt, Transhepatic Variceal Embolization, and Partial Splenic Embolzation in Managing Esophagogastric Variceal Hemorrhage

the Efficacy of Transjugular Intrahepatic Portosystemic Shunt(TIPS) or Partial Splenic Embolzation in combination with Transhepatic Variceal Embolization vs TIPS alone: a randomized controlled parallel study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-14005642
Enrollment
Unknown
Registered
2014-12-06
Start date
2015-01-05
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Portal Hypertension

Interventions

A:partial splenic embolization with percutaneous emboIization of gastroesophageaI varices
B:transjugular intrahepatic portosystemic shunt with percutaneous emboIization of gastroesophageaI varices
C:transjugular intrahepatic portosystemic shunt

Sponsors

the First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. be able to sign up the informed consent and comply by the plan pf treatment and follow-up; 2. acute or recent(in 3 months) variceal hemorrhage; 3. Large varices confirmed by contrast enhanced computed tomography and/or endoscopy.

Exclusion criteria

Exclusion criteria: 1. liver cancer or other malignant tumors; 2. previous TIPS, surgical shunt or spleen resection; 3. more than 50% stenosis or obstruction, and thrombosis or cavernous transformation of portal vein; 4. polycystic disease of liver; 5. failure of heart, lung or kidney, or other complications which treatment contradicted to the trail' management; 6. hepatic encephalopathy; 7. MELD (model for end-stage liver disease) score by 4 or more or Child-Pugh C or higer degree; 8. uncontrolled infection, especially biliary infection; 9. Budd-Chiari syndrome; 10. contraindications to anticoagulation drugs; 11. reject to sign informed consent.

Design outcomes

Primary

MeasureTime frame
variceal rebleeding;

Secondary

MeasureTime frame
procedural complications;variceal recurrence;hepatic encephalopathy;mortality;MELD score changing by 4 or more points or Child-Pugh score by 2 or more;

Countries

China

Contacts

Public ContactHan Xin-Wei
hanxinwei2006@163.com+86 13803842129

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026